SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum... Show more
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where SABS declined for three days, in of 267 cases, the price declined further within the following month. The odds of a continued downward trend are .
The 10-day RSI Indicator for SABS moved out of overbought territory on November 28, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 19 similar instances where the indicator moved out of overbought territory. In of the 19 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
SABS broke above its upper Bollinger Band on November 17, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Momentum Indicator moved above the 0 level on November 17, 2025. You may want to consider a long position or call options on SABS as a result. In of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for SABS just turned positive on November 18, 2025. Looking at past instances where SABS's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SABS advanced for three days, in of 191 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 101 cases where SABS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. SABS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.139) is normal, around the industry mean (27.316). P/E Ratio (0.000) is within average values for comparable stocks, (52.494). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.898). Dividend Yield (0.000) settles around the average of (0.048) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (323.945).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SABS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Industry Biotechnology
A.I.dvisor indicates that over the last year, SABS has been loosely correlated with MGX. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if SABS jumps, then MGX could also see price increases.
| Ticker / NAME | Correlation To SABS | 1D Price Change % | ||
|---|---|---|---|---|
| SABS | 100% | -2.23% | ||
| MGX - SABS | 38% Loosely correlated | +3.55% | ||
| TECX - SABS | 32% Poorly correlated | +0.23% | ||
| BEAM - SABS | 29% Poorly correlated | +1.20% | ||
| INKT - SABS | 28% Poorly correlated | -5.82% | ||
| SLS - SABS | 27% Poorly correlated | +10.96% | ||
More | ||||